Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck

Patients with recurrent or metastatic HNC have a poor response and survival with currently available chemotherapy agents. Thus, new agents are needed. The authors report the results of a phase II trial of irinotecan and cisplatin in patients with metastatic or recurrent HNC.

[1]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[2]  L. Hutchins,et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Lyman,et al.  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Fukuoka,et al.  Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts , 1993, Japanese journal of cancer research : Gann.

[5]  N. Saijo,et al.  Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. , 1996, Cancer research.

[6]  New drug therapy for squamous carcinoma of the head and neck. , 1996, Current opinion in oncology.

[7]  Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. , 1997, Seminars in oncology.

[8]  N. Kemeny,et al.  Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Shah,et al.  Essentials of head and neck oncology , 1998 .

[10]  R. Dunlop,et al.  Cytokines and advanced cancer. , 2000, Journal of pain and symptom management.

[11]  D. Carbone,et al.  Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Topoisomerase I inhibitors in the treatment of head and neck cancer. , 2001, Oncology.

[13]  F. Khuri,et al.  Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Baselga,et al.  Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Kiura,et al.  Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. , 2004, Anticancer research.

[16]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[17]  D. Ilson.  Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. , 2004, Oncology.

[18]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Van Waes,et al.  A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma , 2005, Head & neck.

[20]  C. Waes,et al.  Nuclear Factor-KB as a Common Target and Activator of Oncogenes in Head and Neck Squamous Cell Carcinoma , 2005 .

[21]  C. Van Waes,et al.  Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. , 2005, Advances in oto-rhino-laryngology.

[22]  O. Dirsch,et al.  The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan , 2005, Anti-cancer drugs.

[23]  B Nebiyou Bekele,et al.  Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice , 2006, Clinical Cancer Research.

[24]  Giuseppe Toffoli,et al.  The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Hyae-Young Kim,et al.  A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum‐based chemotherapy , 2006, Cancer.

[26]  E. Shin,et al.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Joo‐Hang Kim,et al.  Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited‐disease small‐cell lung cancer , 2007, Cancer.

[28]  Silvio Garattini,et al.  Pharmacokinetics in cancer chemotherapy. , 2007, European journal of cancer.

[29]  C. Van Waes,et al.  Role of activated nuclear factor‐κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck , 2007, Head & neck.

[30]  R. Labianca,et al.  Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Netterville,et al.  Single Agent Irinotecan for the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN) , 2007 .